Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

BMY 71.49 +0.18 (0.25%)
price chart
Bristol-Myers in Deal for Amylin Valued at $7 Billion
Bristol-Myers Squibb agreed late on Friday to buy Amylin Pharmaceuticals, the maker of a promising new diabetes drug, in a complicated deal that is valued at about $7 billion.
Bristol-Myers to buy Amylin for about $5.3 billion  Reuters
Bristol's Amylin Deal Heralds Acquisition Hunger  Bloomberg
Bristol-Myers Squibb - Abilify
Then it created a SWAT team to exclusively call on nursing homes, where dementia-related psychosis is more prevalent than schizophrenia or bipolar disorder.
BBDO, CDM Said to Win Big Bristol-Myers Squibb Brand
Omnicom agencies BBDO New York and The CDM Group have been given U.S. creative lead responsibilities for Bristol-Myers Squibb's Abilify antidepressant drug, sources said. The brand, which had been at Digitas Health, spent $133.7 million in U.S. ...
How to Profit From Bristol-Myers Squibb's New Cancer Drugs
Bristol-Myers Squibb announced this week that not one but two of its experimental immunotherapy drugs, not chemotherapy drugs, immunotherapy, have shown amazing results in advanced stages of several types of cancer, and the results are long lasting.
Positive long-term results for Bristol-Myers Squibb's Nulojix in organ rejection
US drug major Bristol-Myers Squibb (NYSE: BMY) yesterday presented the data at the 2012 American Transplant Congress in Boston, showing that Nulojix (belatacept), its treatment to prevent organ rejection in patients receiving kidney transplants, was ...
Bristol-Myers Hits Sandoz Over Generic Hepatitis Drug
Law360, New York (June 21, 2012, 7:39 PM ET) -- Bristol-Myers Squibb Co. on Thursday filed suit in Delaware federal court alleging Sandoz Inc.'s plan to make a generic version of the hepatitis B drug Baraclude would lead to infringement of BMS' patent ...
Bristol-Myers authorizes $3 billion share buyback
Drugmaker Bristol-Myers Squibb Co (BMY.N) on Tuesday said its board authorized the repurchase of $3 billion of the company's common stock in addition to the $3 billion share buyback program it announced in 2010.
FDA Once Again Delays Approval Of Apixaban (Eliquis)  Forbes
Pfizer, Bristol-Myers's Eliquis Fails to Win FDA Approval
Pfizer Inc. and Bristol-Myers Squibb Co. failed to gain approval of their top experimental drug, the blood thinner Eliquis, from U.S.
FDA rejects blockbuster Eliquis bid, asks Pfizer, BMS for trial clarification  FierceBiotech
Eliquis held up again by FDA, launch delayed at least six months  Medical Marketing and Media
Bristol Immune Drug Success in Cancer May Spur Industry Race
The early success of an experimental drug from Bristol-Myers Squibb Co. that's designed to unleash the body's immune-system defenses against cancer sets the stage for an industry wide race to produce similar treatments.
Celegene, Bristol Drugs No Better Than Cheaper Treatments
Celgene Corp.'s Abraxane and Bristol-Myers Squibb Co.'s Ixempra breast-cancer drugs worked no better at delaying tumor growth than a less-expensive chemotherapy that's been the backbone of treatment for 20 years.
Paclitaxel tops newer drugs in comparative breast cancer study  PMLiVE